Keel Point, LLC Liquidia Corp Transaction History

Keel Point, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 27, 2022	SELL	$5.14 - $7.38 $592,662 - $850,943	-115,304 Closed	0 $0
Q4 2021 Jan 31, 2022	SELL	$2.71 - $5.17 $108,400 - $206,800	-40,000 Reduced 25.76%	115,304 $561,000
Q3 2021 Nov 04, 2021	BUY	$2.28 - $2.95 $354,093 - $458,146	155,304 New	155,304 $429,000
Q2 2021 Aug 06, 2021	SELL	$2.51 - $3.11 $452,563 - $560,745	-180,304 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$2.6 - $5.79 $130,000 - $289,500	50,000 Added 38.37%	180,304 $532,000
Q3 2020 Nov 18, 2020	BUY	$4.34 - $8.28 $305,991 - $583,781	70,505 Added 117.9%	130,304 $641,000
Q2 2020 Aug 14, 2020	SELL	$4.86 - $11.44 $702,872 - $1.65 Million	-144,624 Reduced 70.75%	59,799 $504,000
Q1 2020 May 01, 2020	BUY	$3.31 - $7.15 $344 - $743	104 Added 0.05%	204,423 $963,000
Q4 2019 Feb 07, 2020	BUY	$3.07 - $5.11 $490,414 - $816,291	159,744 Added 358.37%	204,319 $873,000
Q3 2019 Nov 12, 2019	BUY	$3.29 - $8.24 $98,700 - $247,200	30,000 Added 205.83%	44,575 $159,000
Q2 2019 Aug 08, 2019	BUY	$7.92 - $11.39 $115,434 - $166,009	14,575 New	14,575 $117,000

162

36M

1.79M

380K

Ticker LQDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,362,300
Market Cap $709M
Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...

Get notified when there are updates to the investment portfolio of Keel Point, LLC, based on Form 13F filings with the SEC.

Stay updated on Keel Point, LLC with notifications on news.